Valarcher Jean François, Hägglund Sara, Näslund Katarina, Jouneau Luc, Malmström Ester, Boulesteix Olivier, Pinard Anne, Leguéré Dany, Deslis Alain, Gauthier David, Dubuquoy Catherine, Pietralunga Vincent, Rémot Aude, Falk Alexander, Shevchenko Ganna, Bergström Lind Sara, Von Brömssen Claudia, Vargmar Karin, Zhang Baoshan, Kwong Peter D, Rodriguez María Jose, Garcia Duran Marga, Schwartz-Cornil Isabelle, Taylor Geraldine, Riffault Sabine
Department of Clinical Sciences, Swedish University of Agricultural Sciences, 750 07 Uppsala, Sweden.
Université Paris-Saclay, INRAE, UVSQ, VIM, 78350 Jouy-en-Josas, France.
Vaccines (Basel). 2021 Mar 9;9(3):236. doi: 10.3390/vaccines9030236.
The induction of long-lasting clinical and virological protection is needed for a successful vaccination program against the bovine respiratory syncytial virus (BRSV). In this study, calves with BRSV-specific maternally derived antibodies were vaccinated once, either with (i) a BRSV pre-fusion protein (PreF) and Montanide ISA61 VG (ISA61, = 6), (ii) BRSV lacking the SH gene (ΔSHrBRSV, = 6), (iii) a commercial vaccine (CV, = 6), or were injected with ISA61 alone ( = 6). All calves were challenged with BRSV 92 days later and were euthanized 13 days post-infection. Based on clinical, pathological, and proteomic data, all vaccines appeared safe. Compared to the controls, PreF induced the most significant clinical and virological protection post-challenge, followed by ΔSHrBRSV and CV, whereas the protection of PreF-vaccinated calves was correlated with BRSV-specific serum immunoglobulin (Ig)G antibody responses 84 days post-vaccination, and the IgG antibody titers of ΔSHrBRSV- and CV-vaccinated calves did not differ from the controls on this day. Nevertheless, strong anamnestic BRSV- and PreF-specific IgG responses occurred in calves vaccinated with either of the vaccines, following a BRSV challenge. In conclusion, PreF and ΔSHrBRSV are two efficient one-shot candidate vaccines. By inducing a protection for at least three months, they could potentially improve the control of BRSV in calves.
要成功开展针对牛呼吸道合胞病毒（BRSV）的疫苗接种计划，需要诱导产生持久的临床和病毒学保护。在本研究中，具有BRSV特异性母源抗体的犊牛接受一次疫苗接种，分别为：（i）BRSV融合前蛋白（PreF）和Montanide ISA61 VG（ISA61，n = 6）；（ii）缺失SH基因的BRSV（ΔSHrBRSV，n = 6）；（iii）市售疫苗（CV，n = 6）；或仅注射ISA61（n = 6）。92天后，所有犊牛均用BRSV进行攻毒，并在感染后13天实施安乐死。基于临床、病理和蛋白质组学数据，所有疫苗似乎都是安全的。与对照组相比，PreF在攻毒后诱导出最显著的临床和病毒学保护，其次是ΔSHrBRSV和CV，而PreF疫苗接种犊牛的保护作用与接种后84天的BRSV特异性血清免疫球蛋白（Ig）G抗体反应相关，且在这一天，ΔSHrBRSV和CV疫苗接种犊牛的IgG抗体滴度与对照组无差异。然而，在用任何一种疫苗接种的犊牛中，在BRSV攻毒后均出现了强烈的BRSV和PreF特异性IgG回忆反应。总之，PreF和ΔSHrBRSV是两种有效的单次注射候选疫苗。通过诱导至少三个月的保护作用，它们有可能改善犊牛BRSV的防控。
